C-Telopeptide, A Surrogate Biomarker of Bone Remodeling–Specifically, Osteoclast Cell Activity
When it comes to monitoring response to therapy, whether positive or negative, waiting two years for the next insurance approved bone mineral density (DXA) test results wastes a lot of